Erythroplasia of Queyrat: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(Mahshid)
No edit summary
 
(215 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{SI}}
{{SI}}
{{CMG}} {{AE}} {{Ammu}}
{{CMG}}; {{AE}} {{Swathi}}


{{SK}} EQ
{{SK}} EQ
==Overview==
==Overview==
Erythroplasia of Queyrat was named after Louis Queyrat, a French dermatologist who was head of the dermatology service of l'Hôpital Ricord, a venereal hospital in Paris, now Hôpital Cochin. The pathogenesis of Erythroplasia of Queyrat is characterized by [[squamous cell carcinoma]] in situ of the [[glans penis]]. Erythroplasia of Queyrat is more commonly observed among patients aged 40 years old. The most common risk factor in the development of Erythroplasia of Queyrat is an uncircumcised penis. The mainstay of therapy for Erythroplasia of Queyrat is  imiquimod or 5-fluorouracil for several weeks to months.
Erythroplasia of Queyrat is a [[Penile carcinoma in situ|penile squamous cell carcinoma in situ]] named after Louis Queyrat, a French [[dermatologist]] who was head of the [[dermatology]] service of l'Hôpital Ricord, a [[venereal]] [[hospital]] in Paris, now Hôpital Cochin. The [[pathogenesis]] of erythroplasia of Queyrat is characterized as a [[precancerous]] lesion of [[squamous cell carcinoma]] in situ of the [[glans penis]] and inner [[prepuce]] or [[foreskin]]. Erythroplasia of Queyrat is most commonly observed among white [[male]] [[Patient|patients]] [[Age|aged]] 60 years old and older with [[Human Papillomavirus|Human papilloma virus]] ([[Human papillomavirus|HPV]]) infection or [[Chronic (medicine)|chronic]] [[irritation]] and lack of [[hygiene]] of [[pubic]] area. The most common [[risk factor]] in the [[development]] of erythroplasia of Queyrat is an [[Circumcised|uncircumcised]] [[penis]]. The mainstay of therapy for erythroplasia of Queyrat is  [[imiquimod]] or [[5-fluorouracil]] for several weeks to months.
 
==Historical Perspective==
==Historical Perspective==
*Erythroplasia of Queyrat was named after Louis Queyrat, a French dermatologist who was head of the dermatology service of l'Hôpital Ricord, a venereal hospital in Paris, now Hôpital Cochin.
*Erythroplasia of Queyrat was first discovered and named after Louis Queyrat.<ref>{{cite book | last = Weidner | first = Noel | title = Modern surgical pathology | publisher = Saunders/Elsevier | location = Philadelphia, PA | year = 2009 | isbn = 9781437719581 }}</ref>
*Louis Queyrat was French [[dermatologist]] who was head of the [[dermatology]] service of l'Hôpital Ricord, a [[venereal]] [[hospital]] in Paris, now Hôpital Cochin.
*Tarnovsky originally described erythroplasia of Queyrat in 1891, but it was Queyrat who originated the term erythroplasia in 1911.
 
==Classification==
*Erythroplasia of Queyrat is classified as a [[precancerous]] lesion.
*The earliest stage of [[Squamous cell carcinoma|squamous cell cancer]] of the [[penis]] known as [[Carcinoma in situ|Carcinoma in situ]] [[Carcinoma in situ|(CIS)]]. 
*This is also known as stage 0 of [[penile cancer]].
*In this stage, the [[cancer]] [[Cells (biology)|cells]] are found only in the top layers of [[skin]]; they have not yet grown into the deeper [[Tissue (biology)|tissues]].<ref name="HakenbergCompérat2015">{{cite journal|last1=Hakenberg|first1=Oliver W.|last2=Compérat|first2=Eva M.|last3=Minhas|first3=Suks|last4=Necchi|first4=Andrea|last5=Protzel|first5=Chris|last6=Watkin|first6=Nick|title=EAU Guidelines on Penile Cancer: 2014 Update|journal=European Urology|volume=67|issue=1|year=2015|pages=142–150|issn=03022838|doi=10.1016/j.eururo.2014.10.017}}</ref>
*Depending on the location of the [[Carcinoma in situ|CIS]] on [[penis]], [[Doctor of Medicine|doctors]] may use other names for the [[disease]].
**[[Carcinoma in situ|CIS]] of the [[glans]] or [[prepuce]] is called erythroplasia of Queyrat, presents as [[erythroplakia]].
**[[Carcinoma in situ|CIS]] on the [[shaft]] of the [[penis]] (or other parts of the [[Genital area|genitals]]) is called [[Bowen's disease|Bowen disease]], presents as [[leukoplakia]].
*About 95% of [[Penile cancer|penile cancers]] start in flat [[skin]] [[Cell (biology)|cells]] called [[Squamous epithelium|squamous]] [[Cell (biology)|cells]].
*[[Squamous cell carcinoma]] can start anywhere on the [[penis]].
*Most of these [[Cancer|cancers]] start on the [[prepuce]] or [[foreskin]] (in men who have not been [[Circumcise|circumcised]]) or on the [[glans]].
*These [[Tumor|tumors]] tend to grow slowly. If they're found at an early stage, they can usually be [[Cure|cured]].
 
===Jackson's Staging System for Squamous Cell Carcinoma of Penis===
*[[Squamous cell carcinoma|Squamous cell carcinoma of penis]] may be classified according to [[Jackson's Staging System]] into number subtypes/groups:<ref>Lynch DF Jr. Cancer of the Penis. In: Kufe DW, Pollock RE, Weichselbaum RR, et al., editors. Holland-Frei Cancer Medicine. 6th edition. Hamilton (ON): BC Decker; 2003. Available from: https://www.ncbi.nlm.nih.gov/books/NBK13419/</ref>
 
{| class="wikitable"
|-
!Stage
! Description
|-
| I
| Confined to glans of prepuce
|-
| II
|  Invasion into shaft or corpora
 
|-
| III
| Operable inguinal lymph node metastasis
 
|-
| IV
| Tumor invades adjacent structures; inoperable inguinal lymph node metastasis
 
|}
 
==Pathophysiology==
==Pathophysiology==
*The pathogenesis of Erythroplasia of Queyrat is characterized by [[squamous cell carcinoma]] in situ of the [[glans penis]]<ref name="Lookingbill">Marks, James G; Miller, Jeffery (2006). ''Lookingbill and Marks' Principles of Dermatology'' (4th ed.). Elsevier Inc. Page 63. ISBN 1-4160-3185-5.</ref>
*The [[pathogenesis]] of erythroplasia of Queyrat is characterized by [[squamous cell carcinoma]] ([[Squamous cell carcinoma|SCC]]) in situ of the [[glans penis]]:<ref name="Lookingbill">Marks, James G; Miller, Jeffery (2006). ''Lookingbill and Marks' Principles of Dermatology'' (4th ed.). Elsevier Inc. Page 63. ISBN 1-4160-3185-5.</ref>
**It is a [[premalignant]] [[dermatosis]] that usually occurs on the [[glans penis]] and appears as a well-marginated [[erythematous]] velvety patch or [[plaque]].
**Analogous to [[Bowen's disease]], [[Infiltration (medical)|infiltration]], [[Nodular|nodularity]] or [[ulceration]] often suggest the possibility of progression to an [[Invasive (medical)|invasive]] [[squamous cell carcinoma]]. 
**[[Transformation]] of erythroplasia of Queyrat into an [[Invasive (medical)|invasive]] [[Squamous cell carcinoma|SCC]] is more common than in [[Bowen's disease|Bowen's disease]], with an [[Incidence (epidemiology)|incidence]] varying from 10% to 33%.  This difference could be related to the [[mucosal]] location of the [[disease]].
**When [[Penis|penile]] [[submucosa]] is invaded, the rate of involvement of regional [[lymph nodes]] is about 20%.
**Clinically, the presence of [[ulceration]] and/or [[papillary]] [[lesions]] usually corresponds to progression into an [[Invasive (medical)|invasive]] [[carcinoma]].
===Histopathological Features===
*Low-grade (I-II)<ref name="HakenbergCompérat2015" />
**Well-differentiated [[Lesion|lesions]] show a thickened [[Hyperkeratosis|hyperkeratotic]], and [[Papillomatosis|papillomatous]] [[epidermis]]
**Downward fingerlike projection of atypical [[Squamous cell|squamous cells]] that often appear as concentrically arranged nests of [[Cells (biology)|cells]] surrounding [[keratin]] accumulations ([[keratin]] pearls).
*High-grade (III-IV)
**More poorly differentiated [[squamous cell carcinoma]]
**Shows little or no [[keratinization]]
**Increased [[nuclear]] [[pleomorphism]]
**[[Hyperchromicity|Hyperchromatic]]
**Deeper [[Invasive (medical)|invasion]]; may have areas of [[necrosis]] or [[superinfection]]
 
{| align="right"
|[[File:Erythroplasia of Queyrat.png|thumb|none|300px|Clinical presentation of Erythroplasia of Queyrat [https://openi.nlm.nih.gov/detailedresult.php?img=PMC3981308_cp-2012-3-e63-g001&query=erythroplasia+of+queyrat&it=xg&req=4&npos=1 Source: Department of Urology, Mid-Western Regional Hospital, Dooradoyle, Limerick, Co. Limerick, Ireland - National library of medicine] ]]
|}
 
==Causes==
Besides old [[age]] and lack of [[Circumcise|circumcision]], erythroplasia of Queyrat has been linked to various factors including:
*[[Chronic (medical)|Chronic]] [[irritation]] from retained [[Secretion|secretions]] under the [[foreskin]]<ref name="pmid23667209">{{cite journal| author=Clark PE, Spiess PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE et al.| title=Penile cancer: Clinical Practice Guidelines in Oncology. | journal=J Natl Compr Canc Netw | year= 2013 | volume= 11 | issue= 5 | pages= 594-615 | pmid=23667209 | doi= | pmc=4042432 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23667209  }} </ref>
*Poor [[hygiene]]
*[[Smegma]]
*[[Herpes Genitalis|Genital herpes]] simplex
*[[Heat]]
*[[Friction]]
*[[Trauma]]
*[[Human papilloma virus]] ([[Human papilloma virus|HPV]]) infection, types 16, 18, 31, 33.
 
==Differentiating Erythroplasia of Queyrat from Other Diseases==
*Erythroplasia of Queyrat must be differentiated from other diseases that cause [[squamous cell carcinoma|squamous cell carcinoma of penis]]:
**[[Bowen's disease|Bowen's Disease]]<ref name="BradyMercurio2013">{{cite journal|last1=Brady|first1=Kimberly L.|last2=Mercurio|first2=Mary Gail|last3=Brown|first3=Marc D.|title=Malignant Tumors of the Penis|journal=Dermatologic Surgery|volume=39|issue=4|year=2013|pages=527–547|issn=1076-0512|doi=10.1111/dsu.12029}}</ref>
**Bowenoid Papulosis
**[[Verrucous carcinoma]]
 
==Epidemiology and Demographics==
==Epidemiology and Demographics==
===Age===
*Israel and the United States as well as other industrialized countries, where [[infant]] [[Circumcise|circumcision]] is common, the [[Incidence (epidemiology)|incidence]] of [[carcinoma of the penis|penile squamous cell carcinoma]] is less than 1 per 100,000 [[Male|males]].<ref name="pmid18607597">{{cite journal| author=Bleeker MC, Heideman DA, Snijders PJ, Horenblas S, Dillner J, Meijer CJ| title=Penile cancer: epidemiology, pathogenesis and prevention. | journal=World J Urol | year= 2009 | volume= 27 | issue= 2 | pages= 141-50 | pmid=18607597 | doi=10.1007/s00345-008-0302-z | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18607597  }} </ref>
*Erythroplasia of Queyrat is more commonly observed among patients aged 40 years old.
*[[Squamous cell cancer]] accounts for more than 95% of cases of [[penile cancer]]. This represents a significant [[public health]] problem in several parts of the world where early [[Circumcise|circumcision]] and good [[genital]] [[hygiene]] are less commonly practiced. 
===Gender===
 
*Males are affected with Erythroplasia of Queyrat.
*Erythroplasia of Queyrat is more commonly observed among [[patients]] [[Age|aged]] 60 years old.
 
*[[Male|Males]] are affected with erythroplasia of Queyrat.
 
==Risk Factors==
==Risk Factors==
*Most common risk factor in the development of Erythroplasia of Queyrat is uncircumcised penis.
Most common [[risk factor]] in the [[development]] of erythroplasia of Queyrat is [[Circumcised|uncircumcised]] [[penis]]. Other common [[Risk factor|risk factors]] in the development of erythroplasia of Queyrat include:<ref name="BleekerHeideman2008">{{cite journal|last1=Bleeker|first1=M. C. G.|last2=Heideman|first2=D. A. M.|last3=Snijders|first3=P. J. F.|last4=Horenblas|first4=S.|last5=Dillner|first5=J.|last6=Meijer|first6=C. J. L. M.|title=Penile cancer: epidemiology, pathogenesis and prevention|journal=World Journal of Urology|volume=27|issue=2|year=2008|pages=141–150|issn=0724-4983|doi=10.1007/s00345-008-0302-z}}</ref> <ref name="DouglawiMasterson2017">{{cite journal|last1=Douglawi|first1=Antoin|last2=Masterson|first2=Timothy A.|title=Updates on the epidemiology and risk factors for penile cancer|journal=Translational Andrology and Urology|volume=6|issue=5|year=2017|pages=785–790|issn=22234683|doi=10.21037/tau.2017.05.19}}</ref>
== Diagnosis ==
 
=== Symptoms ===
*[[Smoking]]
*Symptoms of Erythroplasia of Queyrat may include the following:
*[[Obesity]]
:*Red rash on the tip of the penis
*Low [[socio-economic status]]
:*Irritation on the tip of the penis
*Multiple [[Sex (activity)|sex]] partners
===Imaging Findings===
*[[Immunosuppression]]
*There are no imaging study findings associated with Erythroplasia of Queyrat.
*[[Ultraviolet light|Ultraviolet (UV) light exposure]]
== Treatment ==
*[[Human Papilloma Virus|Human papilloma virus]] ([[HPV]])
*[[Phimosis]]
*[[Zoon balanitis|Zoon balantis]]
*Underlying [[Dermatosis|dermatoses]] ([[Lichen Planus|lichen planus]])
*[[Chronic inflammation]], [[irritation]] or [[infection]]
 
==Screening==
There is insufficient [[evidence]] to recommend [[Screening (medicine)|routine screening]] for erythroplasia of Queyrat.<ref name="SalamiMontgomery2017">{{cite journal|last1=Salami|first1=Simpa S.|last2=Montgomery|first2=Jeffrey S.|title=Surveillance strategies in the management of penile cancer|journal=Translational Andrology and Urology|volume=6|issue=5|year=2017|pages=868–873|issn=22234683|doi=10.21037/tau.2017.06.04}}</ref>
 
==Natural History, Complications, and Prognosis==
* If left untreated, patients with erythroplasia of Queyrat may progress to develop [[Invasive (medical)|invasive]] [[squamous cell carcinoma]] of the [[penis]].<ref name="SchlenkerSchneede2019">{{cite journal|last1=Schlenker|first1=Boris|last2=Schneede|first2=Peter|title=The Role of Human Papilloma Virus in Penile Cancer Prevention and New Therapeutic Agents|journal=European Urology Focus|volume=5|issue=1|year=2019|pages=42–45|issn=24054569|doi=10.1016/j.euf.2018.09.010}}</ref>
 
==Diagnosis==
===Diagnostic Study of Choice===
*There are no widely recommended [[Screening test|screening tests]] for [[penile cancer]], and many [[Penile cancer|penile cancers]] can be found early, when they're small and before they have [[Spread of the cancer|spread]] to other parts of the [[body]].<ref name="Damjanov2009">{{cite journal|last1=Damjanov|first1=Ivan|title=The Male Genital System|year=2009|pages=329–338|doi=10.1016/B978-0-323-05594-9.00016-7}}</ref>
*The [[diagnosis]] of erythroplasia of Queyrat is confirmed with [[histological]] [[examination]].
*Delays in the [[diagnosis]] and treatment of [[erythroplasia of Queyrat]] are common because of two main factors. 
**Early [[Penis|penile]] [[Squamous cell carcinoma|SCC]] often has a varying [[Clinical|clinical presentation]], mimicking [[benign]] [[Disorder (medicine)|disorders]].
**[[Patient|Patients]] often tend to disregard minimal [[Genital area|genital]] [[lesions]] for a long time before seeking [[medical]] attention.
Delay in [[diagnosis]] of more than 1 year has been observed in 15% to 20% of [[Patient|patients]], the reasons usually being [[embarrassment]], guilt, [[fear]], personal neglect, or ignorance.
 
===History and Symptoms===
*The [[hallmark]] of erythroplasia of Queyrat is a [[Erythematous|red]], velvety appearing [[rash]] beneath the [[Penis|penile]] [[foreskin]].{{cite web |url=http://www.cancer.ca/en/cancer-information/cancer-type/penile/penile-cancer/precancerous-conditions/?region=bc |title=Precancerous conditions of the penis - Canadian Cancer Society |format= |work= |accessdate=}} 
*The [[Lesion|lesions]] are usually [[solitary]] and occasionally erode or [[Ulcerated lesion|ulcerate]], but [[pain]] is uncommon.
*A positive [[History and Physical examination|history]] of lack of [[Circumcise|circumcision]] and [[lesion]] [[growth]] are suggestive of erythroplasia of Queyrat.
*The most common [[Symptom|symptoms]] of this [[precancerous]] condition include:
 
'''Penile Skin Changes'''
*[[Itching]] and [[Dysuria|burning]] under [[foreskin]]
*Thickening of [[skin]]
*[[Skin]] discoloration
*[[Lump|Lumps]]
*[[Ulcer|Ulcers]]
*[[Rash]]; velvety red under [[foreskin]]
*[[Bleeding]] under [[foreskin]]
*Foul smelling [[discharge]] under [[foreskin]]
 
'''Genitourinary Changes'''
*[[Dysuria]]
*Weak [[Urine|urine stream]]
*[[Loss of sensation]] in [[glans]]
*Inability to fully pull back [[foreskin]] over [[glans]]
 
===Physical Examination===
*The physician will then perform a physical examination of the genital area for possible signs of penile cancer or other health problems.
*Penile lesions (sores) usually affect the skin on the penis.
*This is followed by examination and palpation of the lymph nodes in patient's groin to see if they are swollen.
*If symptoms and/or the exam suggest you might have penile cancer, other tests will be needed. These might include a biopsy and imaging tests.
*[[Patient|Patients]] with erythroplasia of Queyrat usually appear [[Erythematous|red]], velvety appearing [[rash]] beneath the [[Penis|penile]] [[foreskin]].
*[[Physical examination]] of [[Patient|patients]] with erythroplasia of Queyrat is usually remarkable for [[Penis|penile]] [[skin changes]] including [[Erythematous|red]], [[Ulceration|ulcerating]], [[bleeding]], and [[Induration|indurated]] [[lesion]] on the [[glans]] or [[Erythematous|red]] [[Vegetation (pathology)|vegetating]] [[mass]] on the [[Glans penis|glans]].
 
===Laboratory Findings===
 
There are no [[diagnostic]] [[Laboratory findings template|laboratory findings]] associated with erythroplasia of Queyrat.
 
===Treatment===
=== Medical Therapy ===
=== Medical Therapy ===
*The mainstay of therapy for Erythroplasia of Queyrat is  imiquimod or 5-fluorouracil for several weeks to months.
*The mainstay of [[therapy]] for erythroplasia of Queyrat is  [[Imiquimod]] or [[5-fluorouracil|5-fluorouracil]] for several weeks to months.<ref name="ChoiChoi2009">{{cite journal|last1=Choi|first1=Jee Woong|last2=Choi|first2=Mira|last3=Cho|first3=Kwang Hyun|title=A Case of Erythroplasia of Queyrat Treated with Imiquimod 5% Cream and Excision|journal=Annals of Dermatology|volume=21|issue=4|year=2009|pages=419|issn=1013-9087|doi=10.5021/ad.2009.21.4.419}}</ref>
*A [[therapeutic]] regimen of 5% [[5-fluorouracil]] ([[5-fluorouracil|5-FU]]) [[Cream (pharmaceutical)|cream]] applied to [[lesion]](s) twice daily for four to five weeks has produced a high [[cure]] [[rate]] and maintained [[Penis|penile]] integrity and [[Function (biology)|function]].<ref name="AntônioAntônio2016">{{cite journal|last1=Antônio|first1=João Roberto|last2=Antônio|first2=Carlos Roberto|last3=Trídico|first3=Lívia Arroyo|last4=Alves|first4=Fernanda Tomé|last5=Rollemberg|first5=Ivan|title=Erythroplasia of Queyrat treated with topical 5-fluorouracil|journal=Anais Brasileiros de Dermatologia|volume=91|issue=5 suppl 1|year=2016|pages=42–44|issn=0365-0596|doi=10.1590/abd1806-4841.20164595}}</ref> 
*There are several [[Non-invasive (medical)|non-invasive]] treatment options for erythroplasia of Queyrat, including:
**[[Photodynamic therapy]]
**[[Cryosurgery]]
**[[Topical application|Topical agents]]
*[[Pharmacological|Pharmacologic]] [[medical]] [[therapy]] is recommended among all [[Patient|patients]] who develop erythroplasia of Queyrat.
 
=== Surgery ===
=== Surgery ===
*Microscopic shaving (Mohs surgery) can be performed for patients with  aggressive forms of Erythroplasia of Queyrat.
[[Surgery]] is the mainstay treatment of choice for erythroplasia of Queyrat,  and is often the only treatment needed for early stage [[Penile cancer|penile cancers]].  Although, authors have used 5% [[5-Fluorouracil|5-FU]] cream with some success. 
*[[Circumcise|Circumcision]]- recommended when the [[lesion]] is limited to [[Preputial gland|preputial]] [[skin]].
*[[Mohs micrographic surgery|Mohs microscopic surgery]]- for [[Patient|patients]] with  aggressive forms of erythroplasia of Queyrat this form of [[Surgery|surgical]] [[excision]] is effective.
*[[Wide local excision]]- removes the [[tumor]] along with a margin of [[normal]] [[tissue]] around it.
*[[Laser surgery]]- an intense, narrow beam of light (called a [[laser]] beam) to destroy [[Cancer (medicine)|cancer]] [[Cells (biology)|cells]].
*[[Cryosurgery]]- extreme cold to freeze and destroy [[Tissue (biology)|tissue]].
 
===Prevention===
There are no established measures for the prevention of erythroplasia of Queyrat.
 
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}

Latest revision as of 16:40, 27 February 2019

WikiDoc Resources for Erythroplasia of Queyrat

Articles

Most recent articles on Erythroplasia of Queyrat

Most cited articles on Erythroplasia of Queyrat

Review articles on Erythroplasia of Queyrat

Articles on Erythroplasia of Queyrat in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Erythroplasia of Queyrat

Images of Erythroplasia of Queyrat

Photos of Erythroplasia of Queyrat

Podcasts & MP3s on Erythroplasia of Queyrat

Videos on Erythroplasia of Queyrat

Evidence Based Medicine

Cochrane Collaboration on Erythroplasia of Queyrat

Bandolier on Erythroplasia of Queyrat

TRIP on Erythroplasia of Queyrat

Clinical Trials

Ongoing Trials on Erythroplasia of Queyrat at Clinical Trials.gov

Trial results on Erythroplasia of Queyrat

Clinical Trials on Erythroplasia of Queyrat at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Erythroplasia of Queyrat

NICE Guidance on Erythroplasia of Queyrat

NHS PRODIGY Guidance

FDA on Erythroplasia of Queyrat

CDC on Erythroplasia of Queyrat

Books

Books on Erythroplasia of Queyrat

News

Erythroplasia of Queyrat in the news

Be alerted to news on Erythroplasia of Queyrat

News trends on Erythroplasia of Queyrat

Commentary

Blogs on Erythroplasia of Queyrat

Definitions

Definitions of Erythroplasia of Queyrat

Patient Resources / Community

Patient resources on Erythroplasia of Queyrat

Discussion groups on Erythroplasia of Queyrat

Patient Handouts on Erythroplasia of Queyrat

Directions to Hospitals Treating Erythroplasia of Queyrat

Risk calculators and risk factors for Erythroplasia of Queyrat

Healthcare Provider Resources

Symptoms of Erythroplasia of Queyrat

Causes & Risk Factors for Erythroplasia of Queyrat

Diagnostic studies for Erythroplasia of Queyrat

Treatment of Erythroplasia of Queyrat

Continuing Medical Education (CME)

CME Programs on Erythroplasia of Queyrat

International

Erythroplasia of Queyrat en Espanol

Erythroplasia of Queyrat en Francais

Business

Erythroplasia of Queyrat in the Marketplace

Patents on Erythroplasia of Queyrat

Experimental / Informatics

List of terms related to Erythroplasia of Queyrat

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Swathi Venkatesan, M.B.B.S.[2]

Synonyms and keywords: EQ

Overview

Erythroplasia of Queyrat is a penile squamous cell carcinoma in situ named after Louis Queyrat, a French dermatologist who was head of the dermatology service of l'Hôpital Ricord, a venereal hospital in Paris, now Hôpital Cochin. The pathogenesis of erythroplasia of Queyrat is characterized as a precancerous lesion of squamous cell carcinoma in situ of the glans penis and inner prepuce or foreskin. Erythroplasia of Queyrat is most commonly observed among white male patients aged 60 years old and older with Human papilloma virus (HPV) infection or chronic irritation and lack of hygiene of pubic area. The most common risk factor in the development of erythroplasia of Queyrat is an uncircumcised penis. The mainstay of therapy for erythroplasia of Queyrat is imiquimod or 5-fluorouracil for several weeks to months.

Historical Perspective

  • Erythroplasia of Queyrat was first discovered and named after Louis Queyrat.[1]
  • Louis Queyrat was French dermatologist who was head of the dermatology service of l'Hôpital Ricord, a venereal hospital in Paris, now Hôpital Cochin.
  • Tarnovsky originally described erythroplasia of Queyrat in 1891, but it was Queyrat who originated the term erythroplasia in 1911.

Classification

Jackson's Staging System for Squamous Cell Carcinoma of Penis

Stage Description
I Confined to glans of prepuce
II Invasion into shaft or corpora
III Operable inguinal lymph node metastasis
IV Tumor invades adjacent structures; inoperable inguinal lymph node metastasis

Pathophysiology

Histopathological Features

Clinical presentation of Erythroplasia of Queyrat Source: Department of Urology, Mid-Western Regional Hospital, Dooradoyle, Limerick, Co. Limerick, Ireland - National library of medicine

Causes

Besides old age and lack of circumcision, erythroplasia of Queyrat has been linked to various factors including:

Differentiating Erythroplasia of Queyrat from Other Diseases

Epidemiology and Demographics

  • Erythroplasia of Queyrat is more commonly observed among patients aged 60 years old.
  • Males are affected with erythroplasia of Queyrat.

Risk Factors

Most common risk factor in the development of erythroplasia of Queyrat is uncircumcised penis. Other common risk factors in the development of erythroplasia of Queyrat include:[8] [9]

Screening

There is insufficient evidence to recommend routine screening for erythroplasia of Queyrat.[10]

Natural History, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

Delay in diagnosis of more than 1 year has been observed in 15% to 20% of patients, the reasons usually being embarrassment, guilt, fear, personal neglect, or ignorance.

History and Symptoms

  • The hallmark of erythroplasia of Queyrat is a red, velvety appearing rash beneath the penile foreskin."Precancerous conditions of the penis - Canadian Cancer Society".
  • The lesions are usually solitary and occasionally erode or ulcerate, but pain is uncommon.
  • A positive history of lack of circumcision and lesion growth are suggestive of erythroplasia of Queyrat.
  • The most common symptoms of this precancerous condition include:

Penile Skin Changes

Genitourinary Changes

Physical Examination

  • The physician will then perform a physical examination of the genital area for possible signs of penile cancer or other health problems.
  • Penile lesions (sores) usually affect the skin on the penis.
  • This is followed by examination and palpation of the lymph nodes in patient's groin to see if they are swollen.
  • If symptoms and/or the exam suggest you might have penile cancer, other tests will be needed. These might include a biopsy and imaging tests.
  • Patients with erythroplasia of Queyrat usually appear red, velvety appearing rash beneath the penile foreskin.
  • Physical examination of patients with erythroplasia of Queyrat is usually remarkable for penile skin changes including red, ulcerating, bleeding, and indurated lesion on the glans or red vegetating mass on the glans.

Laboratory Findings

There are no diagnostic laboratory findings associated with erythroplasia of Queyrat.

Treatment

Medical Therapy

Surgery

Surgery is the mainstay treatment of choice for erythroplasia of Queyrat, and is often the only treatment needed for early stage penile cancers. Although, authors have used 5% 5-FU cream with some success.

Prevention

There are no established measures for the prevention of erythroplasia of Queyrat.

References

  1. ↑ Weidner, Noel (2009). Modern surgical pathology. Philadelphia, PA: Saunders/Elsevier. ISBN 9781437719581.
  2. ↑ 2.0 2.1 Hakenberg, Oliver W.; Compérat, Eva M.; Minhas, Suks; Necchi, Andrea; Protzel, Chris; Watkin, Nick (2015). "EAU Guidelines on Penile Cancer: 2014 Update". European Urology. 67 (1): 142–150. doi:10.1016/j.eururo.2014.10.017. ISSN 0302-2838.
  3. ↑ Lynch DF Jr. Cancer of the Penis. In: Kufe DW, Pollock RE, Weichselbaum RR, et al., editors. Holland-Frei Cancer Medicine. 6th edition. Hamilton (ON): BC Decker; 2003. Available from: https://www.ncbi.nlm.nih.gov/books/NBK13419/
  4. ↑ Marks, James G; Miller, Jeffery (2006). Lookingbill and Marks' Principles of Dermatology (4th ed.). Elsevier Inc. Page 63. ISBN 1-4160-3185-5.
  5. ↑ Clark PE, Spiess PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE; et al. (2013). "Penile cancer: Clinical Practice Guidelines in Oncology". J Natl Compr Canc Netw. 11 (5): 594–615. PMC 4042432. PMID 23667209.
  6. ↑ Brady, Kimberly L.; Mercurio, Mary Gail; Brown, Marc D. (2013). "Malignant Tumors of the Penis". Dermatologic Surgery. 39 (4): 527–547. doi:10.1111/dsu.12029. ISSN 1076-0512.
  7. ↑ Bleeker MC, Heideman DA, Snijders PJ, Horenblas S, Dillner J, Meijer CJ (2009). "Penile cancer: epidemiology, pathogenesis and prevention". World J Urol. 27 (2): 141–50. doi:10.1007/s00345-008-0302-z. PMID 18607597.
  8. ↑ Bleeker, M. C. G.; Heideman, D. A. M.; Snijders, P. J. F.; Horenblas, S.; Dillner, J.; Meijer, C. J. L. M. (2008). "Penile cancer: epidemiology, pathogenesis and prevention". World Journal of Urology. 27 (2): 141–150. doi:10.1007/s00345-008-0302-z. ISSN 0724-4983.
  9. ↑ Douglawi, Antoin; Masterson, Timothy A. (2017). "Updates on the epidemiology and risk factors for penile cancer". Translational Andrology and Urology. 6 (5): 785–790. doi:10.21037/tau.2017.05.19. ISSN 2223-4683.
  10. ↑ Salami, Simpa S.; Montgomery, Jeffrey S. (2017). "Surveillance strategies in the management of penile cancer". Translational Andrology and Urology. 6 (5): 868–873. doi:10.21037/tau.2017.06.04. ISSN 2223-4683.
  11. ↑ Schlenker, Boris; Schneede, Peter (2019). "The Role of Human Papilloma Virus in Penile Cancer Prevention and New Therapeutic Agents". European Urology Focus. 5 (1): 42–45. doi:10.1016/j.euf.2018.09.010. ISSN 2405-4569.
  12. ↑ Damjanov, Ivan (2009). "The Male Genital System": 329–338. doi:10.1016/B978-0-323-05594-9.00016-7.
  13. ↑ Choi, Jee Woong; Choi, Mira; Cho, Kwang Hyun (2009). "A Case of Erythroplasia of Queyrat Treated with Imiquimod 5% Cream and Excision". Annals of Dermatology. 21 (4): 419. doi:10.5021/ad.2009.21.4.419. ISSN 1013-9087.
  14. ↑ Antônio, João Roberto; Antônio, Carlos Roberto; Trídico, Lívia Arroyo; Alves, Fernanda Tomé; Rollemberg, Ivan (2016). "Erythroplasia of Queyrat treated with topical 5-fluorouracil". Anais Brasileiros de Dermatologia. 91 (5 suppl 1): 42–44. doi:10.1590/abd1806-4841.20164595. ISSN 0365-0596.
Retrieved from "https://www.wikidoc.org/index.php?title=Erythroplasia_of_Queyrat&oldid=1554706"